Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.58 |
| ▸ | LIPE | Q05469 | 14/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590317 | 1.00 | EBP (0.58) | EBPLIPEHDAC11HSD11B1EGLN1 | |
| SCHEMBL12447324 | 1.00 | EBP (0.58) | EBPLIPEHDAC11HSD11B1EGLN1 | |
| SCHEMBL5912 | 0.86 | EBP (0.44) | EBPLIPEEGLN1HRH3 | |
| SCHEMBL12702541 | 0.86 | EBP (0.44) | EBPLIPEEGLN1HRH3 | |
| SCHEMBL5418 | 0.86 | EBP (0.44) | EBPLIPEEGLN1HRH3 | |
| SCHEMBL11524 | 0.85 | EBP (0.60) | EBPLIPEHDAC11HSD11B1EGLN1 | |
| SCHEMBL11677 | 0.83 | LIPE (0.45) | EBPLIPEEGLN1HRH3 | |
| SCHEMBL1589600 | 0.83 | LIPE (0.45) | EBPLIPEEGLN1HRH3 | |
| SCHEMBL11130 | 0.83 | LIPE (0.64) | LIPE | |
| SCHEMBL1590003 | 0.83 | LIPE (0.64) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8703807-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2688881-A1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2686300-A1 | NEW AZASPIRODECANONE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012130679-A1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | CYP51A1, HSD17B7, NR5A1 | EBP 182/4885LIPE 4568/4885HDAC11 10/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | EBP 126/4885LIPE 3/4885HDAC11 1166/4885 |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | TYMS, CDK11A, CDKN1A | EBP 931/4885LIPE 4854/4885HDAC11 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.